Aptose Reports Results for the Third Quarter 2024
08 nov. 2024 16h01 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Special Meeting of Shareholders
05 sept. 2024 16h15 HE
|
Aptose Biosciences, Inc.
Aptose Announces Results from Special Meeting of Shareholders
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30 août 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose Receives $10 Million Through a Facility Agreement with Hanmi;
Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
15 août 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Reports Results for the Second Quarter 2024
08 août 2024 17h06 HE
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Second Quarter 2024
Aptose Announces Results from Annual and Special Meeting of Shareholders
18 juin 2024 17h30 HE
|
Aptose Biosciences, Inc.
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03 juin 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market
Under Nasdaq Rules
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31 mai 2024 08h00 HE
|
Aptose Biosciences, Inc.
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Aptose Reports Results for the First Quarter 2024
14 mai 2024 16h01 HE
|
Aptose Biosciences, Inc.
Aptose Reports Results for the First Quarter 2024
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
06 mai 2024 16h30 HE
|
Aptose Biosciences, Inc.
Aptose to Report First Quarter 2024 Financial Results and
Provide Clinical Strategy Update on Tuesday, May 14, 2024